UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.762

Sortiert nach

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

Leukemia, 2013-08, Vol.27 (8), p.1738-1744

2013

Link zum Volltext

Verfügbarkeit prüfen

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Leukemia, 2016-11, Vol.30 (11), p.2208-2213

2016

Link zum Volltext

Verfügbarkeit prüfen

Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Leukemia, 2010-11, Vol.24 (11), p.1934-1939

2010

Link zum Volltext

Verfügbarkeit prüfen

ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells

Leukemia, 2007-07, Vol.21 (7), p.1549-1560

2007

Link zum Volltext

Verfügbarkeit prüfen

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

Leukemia, 2016-03, Vol.30 (3), p.633-639

2016

Link zum Volltext

Verfügbarkeit prüfen

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

Leukemia, 2007-03, Vol.21 (3), p.529-534

2007

Link zum Volltext

Verfügbarkeit prüfen

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma

Blood cancer journal (New York), 2017-09, Vol.7 (9), p.e600-e600

2017

Link zum Volltext

Verfügbarkeit prüfen

Thalidomide as initial therapy for early-stage myeloma

Leukemia, 2003-04, Vol.17 (4), p.775-779

2003

Link zum Volltext

Verfügbarkeit prüfen

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

Leukemia, 2013-01, Vol.27 (1), p.220-225

2013

Link zum Volltext

Verfügbarkeit prüfen

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

Leukemia, 2003-02, Vol.17 (2), p.427-436

2003

Link zum Volltext

Verfügbarkeit prüfen

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

Leukemia, 2018-03, Vol.32 (3), p.719-728

2018

Link zum Volltext

Verfügbarkeit prüfen

Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis

Journal of internal medicine, 2017-06, Vol.281 (6), p.611-619

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma

Leukemia, 2004-03, Vol.18 (3), p.624-627

2004

Link zum Volltext

Verfügbarkeit prüfen

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy

Bone marrow transplantation (Basingstoke), 2004-07, Vol.34 (2), p.161-167

2004

Link zum Volltext

Verfügbarkeit prüfen

Thalidomide for previously untreated indolent or smoldering multiple myeloma

Leukemia, 2001-08, Vol.15 (8), p.1274-1276

2001

Link zum Volltext

Verfügbarkeit prüfen

Monoclonal gammopathies and associated skin disorders

Journal of the American Academy of Dermatology, 1999-04, Vol.40 (4), p.507-535

1999

Link zum Volltext

Verfügbarkeit prüfen

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category

Leukemia, 2017-07, Vol.31 (7), p.1562-1569

2017

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Value of Bone Marrow Angiogenesis in Multiple Myeloma

Clinical cancer research, 2000-08, Vol.6 (8), p.3111-3116

2000

Link zum Volltext

Verfügbarkeit prüfen

A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine

The New England journal of medicine, 1997-04, Vol.336 (17), p.1202-1207

1997

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy

Bone marrow transplantation (Basingstoke), 2004-08, Vol.34 (3), p.235-239

2004

Link zum Volltext

Verfügbarkeit prüfen

Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression

Leukemia, 2017-01, Vol.31 (1), p.130-135

2017

Link zum Volltext

Verfügbarkeit prüfen

Natural history of t(11;14) multiple myeloma

Leukemia, 2018-01, Vol.32 (1), p.131-138

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains

Leukemia, 2018-03, Vol.32 (3), p.729-735

2018

Link zum Volltext

Verfügbarkeit prüfen

Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma

Bone marrow transplantation (Basingstoke), 2004-09, Vol.34 (6), p.485-490

2004

Link zum Volltext

Verfügbarkeit prüfen

Eligibility for Hematopoietic Stem-Cell Transplantation for Primary Systemic Amyloidosis Is a Favorable Prognostic Factor for Survival

Journal of clinical oncology, 2001-07, Vol.19 (14), p.3350-3356

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.762

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.425)
Mit Volltextzugriff
(1.565)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma

Thalidomide as initial therapy for early-stage myeloma

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy

Thalidomide for previously untreated indolent or smoldering multiple myeloma

Monoclonal gammopathies and associated skin disorders

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category

Prognostic Value of Bone Marrow Angiogenesis in Multiple Myeloma

A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine

Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy

Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression

Natural history of t(11;14) multiple myeloma

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains

Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma

Eligibility for Hematopoietic Stem-Cell Transplantation for Primary Systemic Amyloidosis Is a Favorable Prognostic Factor for Survival

Suchergebnisse filtern